ストックスクリーナーアプリを入手
5.30
0.19%
0.010
アフターアワーズ：
5.28
-0.02
-0.38%
前日終値:
$5.29
開ける：
$5.34
24時間の取引高:
2.36M
Relative Volume:
1.16
時価総額：
$913.89M
収益：
$291.85M
当期純損益:
$554.00K
株価収益率:
-697.37
EPS:
-0.0076
ネットキャッシュフロー:
$27.93M
1週間 パフォーマンス:
-2.39%
1か月 パフォーマンス:
-20.42%
6か月 パフォーマンス:
-32.48%
1年 パフォーマンス:
-9.71%
1日の値動き範囲:
$5.25
$5.475
1週間の範囲:
$5.25
$5.64
52週間の値動き範囲:
$3.805
$10.08
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
名前
Xeris Biopharma Holdings Inc
セクター
電話
844-445-5704
住所
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Compare XERS vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XERS
Xeris Biopharma Holdings Inc
|
5.30 | 912.16M | 291.85M | 554.00K | 27.93M | -0.0076 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Overweight |
| 2025-08-12 | 再開されました | H.C. Wainwright | Buy |
| 2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2023-08-28 | 開始されました | Craig Hallum | Buy |
| 2022-10-21 | 開始されました | Jefferies | Buy |
| 2022-04-28 | 開始されました | Craig Hallum | Buy |
| 2021-11-17 | 開始されました | SVB Leerink | Outperform |
| 2021-10-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-02-18 | 開始されました | Piper Sandler | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Leerink Partners | Outperform |
| 2018-07-16 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Xeris Biopharma Holdings Inc (XERS) 最新ニュース
Market Review: Can Xeris Biopharma Holdings Inc keep up with sector leaders - baoquankhu1.vn
Xeris Biopharma stock faces analyst scrutiny amid pipeline delays and biotech volatility - AD HOC NEWS
Barclays reiterates Xeris Pharmaceuticals stock rating on sales outlook By Investing.com - Investing.com Canada
350,168 Shares in Xeris Biopharma Holdings, Inc. $XERS Purchased by Granahan Investment Management LLC - MarketBeat
Xeris Biopharma (NASDAQ: XERS) officer boosts stake via option exercise - Stock Titan
Divisadero Street Capital Management LP Takes $3.31 Million Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Sold by Rosalind Advisors Inc. - MarketBeat
Xeris Biopharma Holdings (XERS) Price Target Increased by 27.78% to 11.73 - MSN
Transcript : Xeris Biopharma Holdings, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 11 - marketscreener.com
XERS: RECORLEV's rapid growth and pipeline advances drive strong financial and strategic momentum - TradingView
Xeris Biopharma shares rise nearly 3% after Q4 earnings beat and strong 2026 outlook - MSN
Xeris Biopharma (XERS) Q4 2025 Earnings Transcript - AOL.com
Assessing Xeris Biopharma Holdings (XERS) Valuation After Profitability Milestone And 2026 Revenue Guidance - Sahm
XERS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Xeris Pharmaceuticals Q2 2025 Earnings Preview - MSN
Momentum Shift: Will Xeris Biopharma Holdings Inc benefit from seasonalityJuly 2025 Update & Stepwise Trade Signal Implementation - baoquankhu1.vn
Xeris Biopharma (NASDAQ:XERS) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Xeris raises 2025 revenue guidance to $280M–$290M following 49% Q2 growth, led by Recorlev - MSN
Xeris Biopharma Holdings, Inc. Experiences Evaluation Revision Amid Market Dynamics and Performance Trends - Markets Mojo
Xeris Biopharma Hits Day Low of $5.80 Amid Price Pressure - Markets Mojo
Why Is CORT Stock Falling Today? - Stocktwits
HC Wainwright Forecasts Xeris Biopharma Q1 Earnings - MarketBeat
Beth Hecht Sells 16,667 Shares of Xeris Biopharma Holdings Inc (XERS) - GuruFocus
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Decoding Xeris Biopharma Holdings Inc (XERS): A Strategic SWOT I - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Insider Sells $104,168.75 in Stock - MarketBeat
Biopharma Appears a Safe Bet Now, So I'm Adding Two Names - TheStreet Pro
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
HC Wainwright Predicts Xeris Biopharma Q2 Earnings - MarketBeat
XERS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xeris Biopharma Balances New Profitability With Recorlev Patent Battles - Yahoo Finance
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2025 Earnings Call Transcript - Insider Monkey
Xeris Biopharma Holdings, Inc.Common Stock (NQ: XERS - The Chronicle-Journal
Xeris Biopharma Q4 2025 Earnings Call Transcript - MarketBeat
Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative - simplywall.st
Xeris Biopharma Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results - MarketBeat
Beth Hecht 10b5-1 sales reported for XERS (NASDAQ: XERS) - Stock Titan
XERS: Achieved first annual net profit and 43.7% revenue growth, led by Recorlev's strong performance - TradingView
Xeris Biopharma (NASDAQ: XERS) outlines endocrine and neuro focus - Stock Titan
Xeris Biopharma Holdings Inc (XERS) Q4 2025 Earnings Call Highli - GuruFocus
Today's Analyst Update: XERS Rating Reiterated at Buy by HC Wain - GuruFocus
Xeris Biopharma (NASDAQ:XERS) Receives Buy Rating from HC Wainwright - MarketBeat
Xeris Biopharma Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Xeris Biopharma (NASDAQ:XERS) Shares Gap UpHere's What Happened - MarketBeat
Earnings call transcript: Xeris Biopharma’s Q4 2025 earnings beat estimates, stock surges - Investing.com Australia
Xeris Biopharma Q4 Earnings Call Highlights - MarketBeat
Xeris Biopharma Q4 product revenue USD 83.43 million versus Ibes estimate USD 82.3 million - marketscreener.com
Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Xeris Biopharma (XERS) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
XERS Projects Strong Growth for FY26 with Significant Revenue In - GuruFocus
Xeris Biopharma Holdings Inc (XERS) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):